SNSS - Earnings call transcript Q1 2018 | Viracta Therapeutics, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good afternoon, ladies and gentlemen and welcome to the Q1 2019 Sunesis Pharmaceuticals Inc. Earnings Conference Call. At this time, all participants are in a listen-only mode. Later we will conduct a question-and-answer session and instructions will follow at that time. [Operator Instructions] As a reminder, this conference call is being recorded. to Chief conference Vice Financial Development. like host to President, now Quinn, Willie Officer would turn over the your Corporate I and Senior

Willie Quinn

you Deepali Scientific recent Officer; today Hyare, on Vice will of With Chief the Thank a review events, first vecabrutinib Oncology available. and Officer; President, Par will joining Operations; more Clinical Global Misfeldt, and Dayton and corporate Executive will provide overview Chief Dayton Judy all I Vice call Interim for we brief me Fox, XXXX, details Judy President, for all financial Suri, the are us. for the provide quarter will be open which program, then questions, Operations. we

filings during making expectations forward-looking will today's today's conference Before and factors begin, events. concerning by we call, important over the forward-looking in Company's Company's forth such could with to that, turn those call Information not on discussed intentions, today, that set we that materially be represent or statements. is the call beliefs do let are cause to qualified These today's future in let differ With and the the intend actual me statements as forward-looking you release statements to from of results Dayton. we update. press remind SEC, accurate me which

Dayton Misfeldt

vecabrutinib year, year. position advanced joining January, together made look in $X.X the is raise an milestones beginning we of loan cohort. some progress XXXX initiate we XXX the through with financial we Bank. Valley the milligram to have we component vecabrutinib that $XX you exciting us. strengthens escalation as In key XXX a the our announced to significant the refinancing the complete Since we Silicon remainder million Thanks, with January our into for announced Willie. was over Phase thank have we milligram the cohort This X million completed in afternoon the Good for company Xb take of closing program. the of Phase and us study. and the year equity and the open our week, of debt dose Last now

the continue a pre-defined one lead tolerated dose Phase a selective number maximum X in And dose cohort other priority executing refractory Xb is as and the vecabrutinib safety in be BTK mutation. development relapsed and the investigated to malignancies. will trial our or company inhibitor in will X, recommended CLL of for dose escalation the determine non-covalent expansion. asset, of CXXX clinical The advancing on Phase patients the Phase patients the Xb/X our advanced B-cell with activity Our the BTK with Phase and including In cohorts vecabrutinib.

the escalating here already cohort and XXX month the completing Phase made last have XXX significant Xb to the We milligram cohort. in progresses milligram

continue as We showing profile at we of benefits. year vecabrutinib. the last to safety well clinical pharmacodynamic pleased presented with some are as of ASH evidence Today, build profile pharmacokinetic a activity, data and on the good

and Judy EHA provide that on We in to will what will expect at update in more clinical be some a mid-June giving details update.

it proprietary Before our PDKX remind about inhibitor hand remain we I excited to like people Judy, I’d that over SNS-XXX. to

formulation are for trial activities our remains completing Judy? Xb pharmacology manufacturing vecabrutinib. we studies, preclinical focus advancing Phase and While the for primary SNS-XXX,

Judy Fox

Thanks, Dayton.

pharmacodynamics escalate We with overall made and events in data increasing team, progress is now The with at period. leadership, to milligram We nine the on will investigators a to XXX and safety XXX in Pharmacodynamic believe the remains and dose. trial and sites on positioned the in this to CXXXS show no important And this in the patients are evaluation our the milligram. through cohort, on milligram no A supported the safety we patient adverse begin BTK year poster actively and CLL U.S. to characterizing a vecabrutinib mg drug-related dose of EHA clinical year preliminary well a this recently and to are execute safety We plan participating data group. program. We that the mutation cycle serious XXX in milligrams XXX completed continue this are PK the five DLTs include study Europe. have [Indiscernible] remain safety look opened at forward on dose intend oncology activity, and for our level trough very profile pleased U.S. prepared we dose concentrations escalation There In warranted. this with treatment XXX trial the having internal well presentation and five. level. PK vecabrutinib markers as who consistent has to are

milligram some also to We on expect cohort. present data the preliminary XXX

back mature to over cohort data available results. review this turn However, now on will this to more Willie will summer. be later call financial the I

Willie Quinn

In position quarter, Judy. strengthened our vecabrutinib. with the you, extending to balance clinical public confidentially $XX first our and from sheet runway for offering, milestones our financial proceeds gross in important adding Thank million marketed we a through

excited this are quality, invest life science to high about investors chose in offering. the We who

$X.X XXXX well as interest-only for The loan debt new and is a beginning favorable we repayment principal us closing Valley provider payments facility Silicon existing rate the than As the to more we in loan months. refinancing loan. a companies. confidence for previous much our Dayton also debt of existing used potential repayment XXXX, through believe our defer retire loan XX a our The the and the with life announced our of new for repayment terms on new as months loan mentioned, science recently allows vote interest the million any premier lower pipeline over indebtedness. agreement was from the which of on than of with principal includes a XX The agreement Bank, of through

we activities during the from was XXXX. Loss of XXXX total used quarter million first results. We the compared as and on the quarterly cash the during patient was equivalents. operations for add in will in of million million and million In and and the spending XXXX, $X.X $XX.X with vecabrutinib expect additional recruitment to cash to as trial clinical slightly our quarter sites. accelerates $X.X the quarter increase clinical $X.X development Turning we first concentrate to expenses quarter ended operating of cash

open We expect into questions. XXXX. operations With cash fund of call your that, well our fourth to current the to Operator? the quarter let’s

Operator

from of comes question first Cowen Company. Our from Instructions] line Marc Frahm and the [Operator

Your is line open.

Marc Frahm

the taking questions Hi, and on next my for making cohort. through to it thanks congrats

having clear bit wait much at know in conference on next of clarify also presentation, abstracts to how just can I little to going on, update but should the EHA? when at you be we the week If a an the what’s are released for you pretty are versus expect

Dayton Misfeldt

As you Marc the thanks, know question. - for

As you know, the abstracts were months ago. submitted

be would than So, be will that present in But abstract data we the will we��ve what look the that really are the I be up-to-date. to originally. planning information be data of towards presentation to really we put sharing to going more representative

Marc Frahm

any that, types Okay. terms to active referred Thanks. in the being of that of are could be what in being disease rate gotten now trial, of in changes patients And you of for you you you then, you for eligible the anything maybe Have they coming patients background provide? where as this screening like from, cohorts kind the of seen noticeable kind think into dose. you’ve might these

Dayton Misfeldt

sure. provide Yes, Judy some I’ll ask color there.

Judy Fox

us the feeling really allows are fully initially the online at cohort milligram that what year to to an patients site now sales initially, we wind pleased with are and the with our patients all have for amendment to we really and first seeing sites essentially up contribute six with Yes, open screening XXX study. we seen, then this the enroll

Marc Frahm

Thank Okay. you.

Dayton Misfeldt

Thanks, Marc.

Operator

next of from Hartaj question line the comes our from Singh Oppenheimer. And Instructions] [Operator

Your line is open.

Hartaj Singh

very Dayton. remind XXX bit. And you apologize quick noise are and you you got the for I much that the follow-up Thank milligram any the as previous of you. seeing patients new And just of Thank quick sort a background had One, XXX Great. just the two per versus number questions, the to a on through can there cohort, A secondly, are the milligram then, two us cohorts? cohort I three learnings are BID? you getting question. patients little you

Dayton Misfeldt

this. Okay. Thanks, Judy address Hartaj. I’ll ask

Judy Fox

mentioned the a we and XXX call, cohort. five screening have XXX patients we the on in And evaluable Yes, milligram. are into milligram so, enrolling as patients now

the many will up we way, exactly are far learnings, how it’s patients as rounding are cohort. completing But from end that as question. conclude sure And exactly that how the along not to with think, still days and I and the contributions sites. at seeing address to So, amendment, again early increased

it patient be is as that think, we said population last requires attention. that are sick learning I year very patients challenging a and we are can these

Hartaj Singh

kind will thoughts abstract any expected are specifically patients? of fall more to patients extent, expect see between the to versus you. But maybe a the breakdown all or as you see just some ones there in that are NHL that I know see at FL I the and CLL you Judy, Yes, there now there the in then, didn’t we what’s background of in, maybe interested EHA. that type just seeing Thank kind was you of And to them these that cohorts.

Judy Fox

Okay.

chemotherapy. are are fact can So, pre-treated with seeing they patients patients. our vast the heavily be we therapies, majority prior CLL And of in venetoclax’s

treatment of prior now seen have is deflects towards heavily molecularly CLL in patients way targeted who We seen chemotherapy a a a But couple from which in haven’t population. therapies trend pre-treated generally, it the chemotherapy. of

Hartaj Singh

saw – Great. the advice mostly any that agents? – question seen T you or And so like mentioned anything you CAR any or venetoclax. from and therapy Fantastic. seen of you have some venetoclax last you you Have is, to on then newer as just said, confusion

Judy Fox

that ASH T come patients We we on presented prior had CAR therapy study. actually have two at with

Hartaj Singh

Yes.

much. Fantastic. Thank you Okay. very

at forward to update Looking the EHA.

Dayton Misfeldt

Thanks, Hartaj.

Operator

I And comments. no over Dayton turn call time. to Instructions] for further would any back at this to [Operator like additional have we the questions

Dayton Misfeldt

your Thank you our for call and on for today and ongoing participating all support interest.

will into in next there. Good many afternoon. We and EHA updates. progress at you look our interactions months future the to see our over to hope and forward June We of be several

Operator

Ladies today’s for you and conclude and does your have Thank participation day. conference. wonderful gentlemen, a this

disconnect. You may now

Viracta Therapeutics (VIRX) 8 May 192018 Q1 Earnings call transcript